Work

Regnase-1 upregulation via antisense oligonucleotides alleviates pulmonary hypertension

Year: 2026

Type: article

Abstract: Extract Pulmonary arterial hypertension (PAH) is a progressive disease characterized by pulmonary arterial remodelling, leading to right ventricular failure [1]. Genetic background and environmental factors are thought to be involved in the onset of PAH [2]. Accumulating evidence from multiple studies supports the involvement of various inflammatory cytokines, including interleukin (IL)-6 and IL-1, as extrinsic contributors to the pathogenesis of PAH [3–5].

Source: ERJ Open Research

DOI: 10.1183/23120541.00912-2026

Authors: Tadakatsu Inagaki, Makoto Okazawa, Akiko Yamagishi, Ka Man Tse, Xin Ding, Saori Umeki-Mizushima, Ryotaro Asano, Kotaro Akaki, Osamu Takeuchi, Yoshikazu Nakaoka

Institutions: National Cerebral and Cardiovascular Center, Kyoto University

Language: English

Topic: Pulmonary Hypertension Research and Treatments

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $808

Funders: Japan Agency for Medical Research and Development, National Cerebral and Cardiovascular Center, Japan Society for the Promotion of Science, Japan Science and Technology Agency, Janssen Japan

Awards: mRNA構造を標的とした新規免疫炎症制御医薬研究開発, G2227181992, G2957701955, Elucidating the molecular pathogenesis of CTD-associated PAH, G5759265390, G6698808572, G8185691523

OpenAlex ID: W7170136632

FWCI:

Cites:

Cited by:

Related to: